Most cited papers from Asarina Pharma (Sweden)

Asarina Pharma (Sweden)

What are the most cited papers from Asarina Pharma (Sweden)?

The most cited paper from Asarina Pharma (Sweden) is "Treatment of premenstrual dysphoric disorder with the GABAA receptor modulating steroid antagonist Sepranolone (UC1010)—A randomized controlled trial" (Marie Bixo, Karin Ekberg, Inger Sundström Poromaa et al., 2017), with 132 citations. Next come "Acceleration of Amyloidosis by Inflammation in the Amyloid-Beta Marmoset Monkey Model of Alzheimer’s Disease" (78) and "GR3027 antagonizes GABA A receptor-potentiating neurosteroids and restores spatial learning and motor coordination in rats with chronic hyperammonemia and hepatic encephalopathy" (76).

Published FieldAccess

Showing 27 of 27 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Treatment of premenstrual dysphoric disorder with the GABAA receptor modulating steroid antagonist Sepranolone (UC1010)—A randomized controlled trial Marie Bixo, Karin Ekberg, Inger Sundström Poromaa et al. · Psychoneuroendocrinology Open access	2 Mar 2017	132
2	Acceleration of Amyloidosis by Inflammation in the Amyloid-Beta Marmoset Monkey Model of Alzheimer’s Disease Ingrid H.C.H.M. Philippens, Paul R. Ormel, Guus Baarends et al. · Journal of Alzheimer s Disease Open access	20 Sep 2016	78
3	GR3027 antagonizes GABA A receptor-potentiating neurosteroids and restores spatial learning and motor coordination in rats with chronic hyperammonemia and hepatic encephalopathy Maja Johansson, Ana Agustí, Marta Llansola et al. · American Journal of Physiology-Gastrointestinal and Liver Physiology Open access	3 Jul 2015	76
4	A pilot study of golexanolone, a new GABA-A receptor-modulating steroid antagonist, in patients with covert hepatic encephalopathy Sara Montagnese et al. · Journal of Hepatology Open access	21 Apr 2021	58
5	Incidence of hemorrhagic stroke in the general population: validation of data from The Health Improvement Network David Gaist, Mari-Ann A. Wallander, Antonio González‐Pérez et al. · Pharmacoepidemiology and Drug Safety	10 Dec 2012	52
6	GABAA receptor modulating steroid antagonists (GAMSA) are functional in vivo Maja Johansson, Jessica Strömberg, Gianna Ragagnin et al. · The Journal of Steroid Biochemistry and Molecular Biology Open access	3 Nov 2015	38
7	Clinical and Budget Impact of Treating Preoperative Anemia in Major Orthopedic Surgery—A Retrospective Observational Study Sike Wan, Vibeke Sparring, David A. Cabrales et al. · The Journal of Arthroplasty Open access	15 Jun 2020	34
8	Golexanolone, a GABAA receptor modulating steroid antagonist, restores motor coordination and cognitive function in hyperammonemic rats by dual effects on peripheral inflammation and neuroinflammation Gergana Mincheva, Carla Giménez‐Garzó, Paula Izquierdo‐Altarejos et al. · CNS Neuroscience & Therapeutics Open access	26 Jul 2022	33
9	Neuroinflammation alters GABAergic neurotransmission in hyperammonemia and hepatic encephalopathy, leading to motor incoordination. Mechanisms and therapeutic implications Marta Llansola, Yaiza M. Arenas, María Sancho‐Alonso et al. · Frontiers in Pharmacology Open access	15 Mar 2024	30
10	Intra-urban variation of antibiotic utilization in children: influence of socio-economic factors Karin Henricson, Eva Melander, Sigvard Mölstad et al. · European Journal of Clinical Pharmacology	11 Nov 1998	30
11	Socioeconomic factors, morbidity and drug utilization—an ecological study Karin Henricson, Pål Stenberg, Gerhard Rametsteiner et al. · Pharmacoepidemiology and Drug Safety	Jul 1998	29
12	Golexanolone improves fatigue, motor incoordination and gait and memory in rats with bile duct ligation Yaiza M. Arenas, Paula Izquierdo‐Altarejos, Mar Martinez‐García et al. · Liver International Open access	27 Nov 2023	19
13	Enhanced Bioavailability and Reduced Variability of Dasatinib and Sorafenib with a Novel Amorphous Solid Dispersion Technology Platform Hans Lennernäs, Magnus Brisander, Charlotta Liljebris et al. · Clinical Pharmacology in Drug Development Open access	29 May 2024	15
14	The GABA system, a new target for medications against cognitive impairment—Associated with neuroactive steroids Torbjörn Carl Bäckström, Şahruh Türkmen, Roshni Das et al. · Journal of Internal Medicine Open access	30 Jul 2023	14
15	Neurosteroid Activation of GABA-A Receptors: A Potential Treatment Target for Symptoms in Primary Biliary Cholangitis? Aaron Wetten, Laura Ogle, George F. Mells et al. · Canadian Journal of Gastroenterology and Hepatology Open access	6 Dec 2022	14
16	Allopregnanolone and its antagonist modulate neuroinflammation and neurological impairment Torbjörn Carl Bäckström, Magnus Doverskog, Thomas P. Blackburn et al. · Neuroscience & Biobehavioral Reviews Open access	11 Apr 2024	11
17	Golexanolone reduces glial activation in the striatum and improves non-motor and some motor alterations in a rat model of Parkinson's disease Paula Izquierdo‐Altarejos, Yaiza M. Arenas, Mar Martinez‐García et al. · Frontiers in Aging Neuroscience Open access	21 Jun 2024	10
18	Determination of cyclohexanone in aqueous solutions stored in PVC bags by isotope dilution gas chromatography—mass spectrometry Olle Falk, Sven P. Jacobsson · Journal of Pharmaceutical and Biomedical Analysis	1989	9
19	Extra-Synaptic GABAA Receptor Potentiation and Neurosteroid-Induced Learning Deficits Are Inhibited by GR3027, a GABAA Modulating Steroid Antagonist Sara K. S. Bengtsson, Jessica Sjöstedt, Evgenya Malinina et al. · Biomolecules Open access	9 Oct 2023	6
20	Isoallopregnanolone Inhibits Estrus Cycle-Dependent Aggressive Behavior Torbjörn Carl Bäckström, Sara K. S. Bengtsson, Jessica Sjöstedt et al. · Biomolecules Open access	20 Jun 2023	6
21	Potassium binders in clinical practice: understanding potassium binder use in contemporary Swedish healthcare—the DEMONSTRATE database Hans Furuland, Anders Olof Larsson, Per Bjellerup et al. · BMC Nephrology Open access	28 Apr 2025	5
22	Comedication of Proton Pump Inhibitors and Dasatinib Is Common in CML but XS004, a Novel Amorphous Solid Dispersion Formulation of Dasatinib, Provides Improved Uptake and Low pH-Dependency, Minimizing Unwanted Drug-Drug Interactions Gunnar Larfors, Hans Lennernäs, Charlotta Liljebris et al. · Blood	15 Nov 2022	4
23	EASL-AASLD Delphi consensus statement on surrogate endpoints and real-world evidence in primary biliary cholangitis Cynthia Levy et al. · Journal of Hepatology Open access	27 May 2026	2
24	Golexanolone affords sustained microglia and astrocytes activation improvement in a rat model of Parkinson’s disease Gergana Mincheva, María A. Pedrosa, Maribel Vázquez et al. · Frontiers in Immunology Open access	3 Sep 2025	1
25	Golexanolone Attenuates Neuroinflammation, Fatigue, and Cognitive and Motor Impairment in Diverse Neuroinflammatory Disorders Marta Llansola, Gergana Mincheva, Yaiza M. Arenas et al. · Pharmaceuticals Open access	18 Nov 2025	0
26	Golexanolone affords sustained improvement of Parkinson's symptoms in rats by reducing microglia activation that restores the glutamate-GABA-dopamine pathway María A. Pedrosa, Gergana Mincheva, Mar Martinez‐García et al. · Neuropharmacology Open access	5 Nov 2025	0
27	GOLEXANOLONE IMPROVES PERIPHERAL INFLAMMATION, FATIGUE, LOCOMOTOR GAIT, MOTOR INCOORDINATION AND SHORT-TERM MEMORY IN RATS WITH CHOLESTASIS AND HEPATIC ENCEPHALOPATHY DUE TO BILE DUCT LIGATION Yaiza Ma Arenas Ortiz, Paula Izquierdo Altarejos, Mar Martinez García et al. · IBRO Neuroscience Reports Open access	Oct 2023	0

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.